Context Therapeutics Inc. (CNTX)
(Delayed Data from NSDQ)
$2.48 USD
-0.02 (-0.80%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.48 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CNTX 2.48 -0.02(-0.80%)
Will CNTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CNTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CNTX
Is CareCloud (CCLD) Stock Outpacing Its Medical Peers This Year?
Are You Looking for a Top Momentum Pick? Why Context Therapeutics Inc. (CNTX) is a Great Choice
CNTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Context Therapeutics Inc. (CNTX) Upgraded to Buy: Here's Why
Nasdaq ETF's First Six-week Rally Since Jan 2020: Stock Winners
Other News for CNTX
Buy Rating Affirmed for Context Therapeutics Amid Strong Financials and Promising CLDN6-Targeting Therapies
Context Therapeutics GAAP EPS of -$0.04
Buy Rating Affirmed for Context Therapeutics as CTIM-76 Shows Promise and Strategic Team Expands Ahead of Clinical Trials
Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results
Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations